同种异基因CAR-T治疗复发难治多发性骨髓瘤四例报告及文献复习
该研究报告4例复发/难治多发性骨髓瘤患者接受HLA不全相合供者来源CAR-T细胞治疗的安全性和有效性。4例中3例按计划完成输注,2例达部分缓解、1例微小缓解、1例疾病稳定;中位无进展生存4周、总生存63周。结论提示可能出现GVHD,CAR-T细胞体内扩增低、持续时间短可能是影响疗效持久的主要因素。
要点
- 异基因CAR-T治疗RRMM可出现GVHD,需监测嵌合状态与临床表现。
- 输注后早期有临床反应但疗效不能维持,中位PFS仅4周。
- CAR-T体内扩增倍数低、存活时间短可能是疗效不持久的主要原因。
核心结论
- 小样本研究显示同种异基因CAR-T细胞治疗RRMM可能出现GVHD。
- 回输后早期有临床反应,但疗效不能维持。
- CAR-T细胞体内扩增倍数低、持续时间短可能是影响疗效持久的主要因素。
研究设计与样本
- 采集HLA不全相合健康供者外周血淋巴细胞制备CAR-T细胞,治疗4例RRMM患者(男1例、女3例)。
- 细胞来源3例为亲缘间HLA半相合供者,1例为HLA完全不合的无血缘供者。
- 4例经FC方案预处理后回输CART-19细胞1×10(7)/kg(第0天)及CART-BCMA细胞4.7(4.0~6.8)×10(7)/kg分次输注(40%第1天、60%第2天)。
主要发现
- 4例中3例按研究计划成功输注,1例因第3天高热和肌酐升高延迟1天输注。
- 不良反应包括≥3级血液学毒性2例、≥3级CRS 1例、1级CRES 1例、APTT延长3例、肿瘤溶解综合征1例、STR混合嵌合及临床GVHD表现1例。
- 按IMWG标准,2例达PR、1例MR、1例SD。
- 中位无进展生存4(3~5)周,总生存63(3~81)周。
- CAR-T细胞在患者体内中位扩增2.20(1.93~14.01)倍,中位存活时间10(8~36)d。
关键数值与推荐
- 疗效按IMWG标准评估:2例PR、1例MR、1例SD。
- CART-19回输剂量1×10(7)/kg(第0天),CART-BCMA回输总剂量4.7(4.0~6.8)×10(7)/kg分次输注。
临床怎么用
- 异基因CAR-T治疗RRMM需警惕GVHD,应监测STR嵌合状态及临床GVHD表现。
- 回输后需监测CRS、CRES、APTT延长、肿瘤溶解综合征及血液学毒性。
- 因扩增低且持续时间短,疗效可能不持久,需考虑维持或联合策略。
局限性
- 样本量仅4例,结论需更大样本验证。
- 随访时间有限,长期安全性及疗效未充分评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the safety and efficacy of allogeneic CAR-T cells in the treatment of relapsed/refractory multiple myeloma (RRMM) . Methods: CAR-T cells were prepared from peripheral blood lymphocytes of HLA mismatch healthy donors. Median age was 55 (48-60) . Allogeneic cells were derived from 3 HLA haploidentical donors and 1 HLA completely mismatch unrelated donor. Four patients with RRMM were conditioned with FC regimen followed by CAR-T cell transfusion. They were infused into CART-19 (1×10(7)/kg on day 0) and (4.0-6.8) ×10(7)/kg CART-BCMA cells as split-dose infusions (40% on day 1 and 60% on day 2) . The adverse reactions and clinical efficacy were observed during follow-up after infusion, and the amplification and duration of CAR-T cells in vivo were monitored by PCR technique. Results: CAR-T cells were successfully infused in 3 of the 4 RRMM patients according to the study plan, and the infusion in one patient was delayed by 1 day due to high fever and elevated creatinine levels on day 3. The side effects included hematological and non-hematological toxicity, grade 3 hematological toxicity in 2 patients, grade 3 CRS in 1 one, grade 1 CRES in 1 one, prolonged APTT in 3 ones, tumor lysis syndrome in 1 one, mixed chimerism detected STR and clinical GVHD manifestation in 1 one. According to the efficacy criterias of IMWG, 2 patients acquired PR, 1 MR, and 1 SD respectively. Progression-free survival was 4 (3-5) weeks and overall survival was 63 (3-81) weeks. CAR T cells were amplified 2.2 (2-14) times in the patients with a median survival time of 10 (8-36) days. Conclusions: Small sample studies suggested that GVHD may be present in the treatment of RRMM with allogeneic CAR-T cells. There were early clinical transient events after transfusion. Low amplification and short duration of CAR-T cells in vivo may be the main factors affecting the efficacy. 目的: 探讨同种异基因CAR-T细胞治疗复发/难治型多发性骨髓瘤(RRMM)的安全性和有效性。 方法: 采集HLA不全相合健康供者外周血淋巴细胞制备CAR-T细胞治疗4例RRMM患者,男1例、女3例。细胞来源3例为亲缘间HLA半相合供者,1例为HLA完全不合的无血缘供者。4例RRMM患者经FC方案(氟达拉滨+环磷酰胺)预处理后进行CAR-T细胞的回输,第0天回输CART-19细胞1×10(7)/kg、第1~2天分别回输CART-B细胞成熟抗原(BCMA)细胞4.7(4.0~6.8)×10(7)/kg的40%和60%(例4于第4天回输CART-BCMA细胞的60%)。 结果: 4例RRMM患者完成了CAR-T细胞输注后,CAR-T细胞在患者体内中位扩增2.20(1.93~14.01)倍,中位存活时间为10(8~36)d;根据IMWG疗效标准,2例达部分缓解(PR)、1例为微小缓解(MR)、1例为疾病稳定(SD)。不良反应包括血液学和非血液学不良反应,≥3级血液学不良反应2例、≥3级细胞因子释放综合征(CRS)1例、1级CAR-T治疗后急性反应期的中枢神经系统并发症(CRES)1例,3例患者出现APTT延长、1例患者出现肿瘤溶解综合征,1例检测到STR为混合嵌合状态,临床判断出现GVHD。无进展生存时间为4(3~5)周、总生存时间为63(3~81)周。 结论: 小样本研究显示同种异基因CAR-T细胞治疗RRMM可能会出现GVHD;回输后早期有临床反应,但疗效不能维持。同种异基因CAR-T细胞在体内扩增倍数低,持续时间短,可能是影响疗效持久的主要因素。.
引用
- Yan LZ, Shang JJ, Shi XL, et al. [Allogeneic CAR-T for treatment of relapsed and/or refractory multiple myeloma: four cases report and literatures review]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31495131. doi:10.3760/cma.j.issn.0253-2727.2019.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。